Hexarelin vs GHRP-2: Which Growth Hormone Peptide Is Stronger?

Among growth hormone secretagogues, Hexarelin and GHRP-2 are two of the most potent. Both bind to ghrelin receptors and trigger GH release from the pituitary. But they have different potency profiles, different desensitization patterns, and different secondary effects that matter for research design.

How Both Peptides Work

Hexarelin and GHRP-2 are both synthetic hexapeptides that act as ghrelin mimetics. They bind to the GHS-R1a receptor (growth hormone secretagogue receptor) in the pituitary and hypothalamus, triggering a pulse of GH release. They also have some direct pituitary action independent of the hypothalamus.

Neither peptide releases GH continuously — they trigger episodic pulses, mimicking the natural pulsatile pattern of GH secretion.

GH Release Potency

This is where the comparison gets interesting. In head-to-head studies, Hexarelin consistently produces higher peak GH concentrations than GHRP-2 at equivalent doses. A study published in the European Journal of Endocrinology showed Hexarelin achieved significantly higher GH peaks than GHRP-2 in healthy adults.

In terms of raw GH-releasing power, Hexarelin is generally considered the strongest of the GHRP family.

View Hexarelin →

Desensitization: The Key Differentiator

Here is where GHRP-2 has an advantage. Hexarelin desensitizes the GHS-R1a receptor relatively quickly. With repeated daily administration, the GH response blunts noticeably within weeks. Some research suggests the pituitary becomes partially refractory to Hexarelin’s signal.

GHRP-2 desensitizes more slowly. This makes it better for research protocols that require sustained GH pulsing over multiple weeks without the need for cycling off to restore receptor sensitivity.

View GHRP-2 →

Cortisol and Prolactin Co-Secretion

Both peptides elevate cortisol and prolactin alongside GH. This is a consistent finding across GHRPs and is related to their action on pituitary cell subtypes beyond just somatotrophs.

Hexarelin tends to produce higher cortisol co-secretion than GHRP-2 in most studies. For research protocols where cortisol elevation is a confounding variable, GHRP-2 may be preferable.

Cardioprotective Effects: Hexarelin’s Unique Profile

One area where Hexarelin stands apart is cardiac research. Hexarelin has been studied specifically for cardioprotective effects that appear to be independent of its GH-releasing action. It binds to a cardiac receptor (CD36) and has shown protective effects in cardiac ischemia models.

This cardiac research angle has generated interest in Hexarelin beyond GH studies. For researchers specifically interested in cardiac protection, Hexarelin has a literature base that GHRP-2 lacks.

Head-to-Head Summary

Synergy with GHRH Peptides

Both Hexarelin and GHRP-2 work synergistically with GHRH analogs like CJC-1295. Combining a GHRP with a GHRH amplifies the GH pulse significantly — GHRH sets the stage, the GHRP triggers the release. Hexarelin plus GHRH produces extremely high acute GH peaks. GHRP-2 plus GHRH produces strong, sustained peaks with less receptor fatigue.

Summary of Key Research References

Written by the NorthPeptide Research Team